Erschienen in:
27.04.2020 | ASO Author Reflections
ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy
verfasst von:
Talia Golan, Alex Barenboim, Nir Lubezky
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 10/2020
Einloggen, um Zugang zu erhalten
Excerpt
The best chance for prolonged survival or cure in patients with pancreatic ductal adenocarcinoma (PDAC) is multimodal treatment that includes chemotherapy and curative resection. In recent years, FOLFIRINOX has proved to be the most efficacious chemotherapeutic regimen, with an unprecedented median survival rate of 54% when administered as adjuvant treatment following curative resection.
1 Recent data also indicate that some patients with borderline-resectable pancreatic cancer (BRPC) benefit from neoadjuvant FOLFIRINOX, and that surgical resection in patients who exhibit significant response to chemotherapy is more likely to result in margin-negative resection and improved survival.
2,3 However, there are currently no identifiable biomarkers that predict which patients will respond to neoadjuvant treatment. …